Zydus Lifesciences gets FDA approval for Bortezomib for Injection
Zydus Lifesciences (previously called Cadila Healthcare) said that it has secured final approval from the US Food and Drug Administration (FDA) to market Bortezomib for Injection, 3.5 mg/vial, Single-Dose Vial. Bortezomib for Injection is the generic of Velcade (bortezomib), which has a market size of $1.17bn as per IQVIA MAT March 2022. It is used […]